NCT01684150 - A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

February 29, 2016

Conditions

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeMyeloproliferative Disorders

Interventions

DRUG

EPZ-5676

MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.

Trial Locations (8)

Memorial Sloan Kettering Cancer Center, New York

Duke University Health System, Durham

Sarah Cannon Research Institute, Nashville

Northwestern University, Chicago

UT MD Anderson Cancer, Houston

Mayo Clinic Scottsdale-Phoenix, Scottsdale

Universitätsklinikum Ulm, Ulm

Erasmus University Medical Center, Rotterdam